Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine.
cholangiocarcinoma
molecular signatures
precision medicine
targeted therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 May 2021
25 May 2021
Historique:
received:
30
04
2021
revised:
17
05
2021
accepted:
19
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Cholangiocarcinomas (CCAs) are heterogeneous biliary tract malignancies with dismal prognosis, mainly due to tumor aggressiveness, late diagnosis, and poor response to current therapeutic options. High-throughput technologies have been used as a fundamental tool in unveiling CCA molecular landscape, and several molecular classifications have been proposed, leading to various targeted therapy trials. In this review, we aim to analyze the critical issues concerning the status of precision medicine in CCA, discussing molecular signatures and clusters, related to both anatomical classification and different etiopathogenesis, and the latest therapeutic strategies. Furthermore, we propose an integrated approach comprising the CCA molecular mechanism, pathobiology, clinical and histological findings, and treatment perspectives for the ultimate purpose of improving the methods of patient allocations in clinical trials and the response to personalized therapies.
Identifiants
pubmed: 34070643
pii: ijms22115613
doi: 10.3390/ijms22115613
pmc: PMC8199244
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Hepatology. 2020 Oct;72(4):1253-1266
pubmed: 31925805
Gastroenterology. 2013 Apr;144(4):829-40
pubmed: 23295441
Am J Clin Oncol. 2018 Jul;41(7):649-655
pubmed: 27849649
Br J Cancer. 2018 Apr;118(7):966-971
pubmed: 29527009
Lancet Oncol. 2012 Feb;13(2):181-8
pubmed: 22192731
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Expert Opin Investig Drugs. 2021 Apr;30(4):317-324
pubmed: 33054456
Oncotarget. 2014 May 15;5(9):2839-52
pubmed: 24867389
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Int J Mol Sci. 2018 May 09;19(5):
pubmed: 29747443
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
Nat Genet. 2013 Dec;45(12):1474-8
pubmed: 24185513
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Proc Natl Acad Sci U S A. 2017 May 9;114(19):E3806-E3815
pubmed: 28439013
BMJ Open. 2017 Jun 10;7(6):e014961
pubmed: 28601826
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Br J Cancer. 2013 Aug 20;109(4):915-9
pubmed: 23900219
Hepatol Int. 2020 Mar;14(2):288-295
pubmed: 32100259
J Clin Med. 2019 Dec 06;8(12):
pubmed: 31817761
Ann Oncol. 2014 Aug;25(8):1597-603
pubmed: 24827133
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Int J Mol Sci. 2017 Jan 13;18(1):
pubmed: 28098760
Br J Cancer. 2008 Jan 29;98(2):418-25
pubmed: 18087285
Cell Rep. 2017 Jun 27;19(13):2878-2880
pubmed: 28658632
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
BMC Cancer. 2015 Jul 21;15:530
pubmed: 26189560
J Hepatol. 2020 Aug;73(2):315-327
pubmed: 32173382
Br J Cancer. 2020 Sep;123(7):1047-1059
pubmed: 32694694
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536
pubmed: 33215952
Hepatology. 2021 Jan;73 Suppl 1:62-74
pubmed: 32304327
Oncology. 2012;82(3):175-9
pubmed: 22433475
Liver Int. 2019 May;39 Suppl 1:19-31
pubmed: 30851228
J Hepatol. 2015 Nov;63(5):1220-8
pubmed: 26119688
Transl Gastroenterol Hepatol. 2018 Jul 12;3:40
pubmed: 30148225
Clin Colorectal Cancer. 2014 Jun;13(2):81-6
pubmed: 24512954
Nat Genet. 2012 May 06;44(6):690-3
pubmed: 22561520
Eur J Cancer. 2017 Dec;87:122-130
pubmed: 29145038
Invest New Drugs. 2012 Aug;30(4):1646-51
pubmed: 21748296
Cancer Treat Rev. 2019 Jan;72:45-55
pubmed: 30476750
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Expert Opin Investig Drugs. 2021 Apr;30(4):301-307
pubmed: 33683991
Nature. 2010 Jun 17;465(7300):966
pubmed: 20559394
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4):
pubmed: 31371345
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Cancer Discov. 2021 Oct;11(10):2488-2505
pubmed: 33926920
Oncotarget. 2016 Aug 9;7(32):52354-52363
pubmed: 27429047
Hepatology. 2010 Sep;52(3):975-86
pubmed: 20607690
World J Gastrointest Oncol. 2012 May 15;4(5):94-102
pubmed: 22645632
J Hepatol. 2017 Jan;66(1):102-115
pubmed: 27593106
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Cancer Immunol Immunother. 2021 Apr;70(4):1001-1014
pubmed: 33095329
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
Ann Oncol. 2015 May;26(5):943-949
pubmed: 25632066
Hepatology. 2018 Sep;68(3):949-963
pubmed: 29278425
Cancer. 2016 Feb 15;122(4):574-81
pubmed: 26540314
Hepatology. 2020 Sep;72(3):965-981
pubmed: 31875970
Ann Oncol. 2013 Dec;24(12):3061-5
pubmed: 24146220
J Hepatol. 2020 Jan;72(1):95-103
pubmed: 31536748
Dig Liver Dis. 2020 Dec;52(12):1430-1442
pubmed: 32952071
Cancer. 2019 Mar 15;125(6):902-909
pubmed: 30561756
Dig Liver Dis. 2020 Nov;52(11):1282-1293
pubmed: 32893173
Brief Bioinform. 2020 Dec 1;21(6):2011-2030
pubmed: 31792509
Eur J Cancer. 2019 Oct;120:31-39
pubmed: 31476489